OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment